Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 11:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 39 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Aspirin 325mg Clear all

Conditions: Body Weight
Interventions: Aspirin 81mg, Aspirin 325mg; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 40 Years to 70 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Venous Thromboembolism
Interventions: Dalteparin sodium, Dalteparin sodium/aspirin; Drug
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Depression, Depressive Disorder, Major Depressive Disorder, Treatment Resistant Depression
Interventions: Aspirin 325mg, Placebo Oral Tablet; Drug
Lead sponsor: Jessica Harder; Other
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Effect of Drug
Interventions: Aspirin 325mg; Drug
Lead sponsor: Hematology Oncology Associates of Central New York; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: East Syracuse, New York

Conditions: Platelet Aggregation Inhibitors, Aspirin, Ticagrelor, RNA
Interventions: Aspirin, Ticagrelor; Drug
Lead sponsor: Duke University; Other
Eligibility: 30 Years to 75 Years
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions: Aspirin 325mg, Placebo; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 4
States / cities: Tampa, Florida • Portland, Oregon • Charlottesville, Virginia + 1 more

Conditions: Atrial Fibrillation, Stroke, Bleeding
Interventions: Antiplatelet-only strategy, Oral Anticoagulant plus background antiplatelet therapy; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 3,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 51
States / cities: Little Rock, Arkansas • Los Angeles, California • Stanford, California + 40 more

Conditions: HIV Infection
Interventions: Aspirin 325mg, Antiretroviral therapy (ART); Drug
Lead sponsor: Hennepin Healthcare Research Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hypercholesterolemia, Flushing
Interventions: Apple pectin, Aspirin 325 mg, Placebo; Other · Drug
Lead sponsor: Patrick Moriarty, MD, FACP, FACC; Other
Eligibility: 21 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Melanoma (Skin)
Interventions: Aspirin 81 mg, Aspirin 325mg, Placebo oral tablet; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy
Interventions: Aspirin, Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 50 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Upper Gastrointestinal Mucosal Damage
Interventions: acetylsalicylic acid; Drug
Lead sponsor: PLx Pharma; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 204 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 6
States / cities: Jupiter, Florida • South Miami, Florida • Oklahoma City, Oklahoma + 3 more

Conditions: Prostate Cancer
Interventions: Aspirin, Placebo; Drug
Lead sponsor: University of Washington; Other
Eligibility: 45 Years to 74 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Aspirin Sensitivity
Interventions: Aspirin; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 55 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Common Cold, Pharyngitis, Fever, Congestion, Rhinorrhea, Cough, Sore-throat, Sore Throats Viral, Malaise, Headache, Runny Nose, Sneezing
Interventions: Wintergreen Throat Spray and Aspirin Tablet, Aspirin Throat Spray and Placebo Tablet, Wintergreen Throat Spray and Placebo Tablet, Placebo Throat Spray and Placebo Tablet; Drug · Dietary Supplement · Other
Lead sponsor: Applied Biological Laboratories Inc; Other
Eligibility: 18 Years to 65 Years
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 6
States / cities: Irvine, California • Washington D.C., District of Columbia • Atlanta, Georgia + 3 more

Conditions: Ketorolac, Joint Fusion
Interventions: great toe (1st metatarsophalangeal joint) fusion, IV Ketorolac, Ketorolac Pill, 5/325mg Oxycodone-Acetaminophen, Aspirin 81Mg Ec Tab; Procedure · Drug
Lead sponsor: Rothman Institute Orthopaedics; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Stable Angina
Interventions: Intravenous Glycoprotein inhibitor + ASA, Clopidogrel, Antiplatelet Therapy (ASA, Clopidogrel); Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Respiratory Distress Syndrome
Interventions: Aspirin, Lactose powder; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 16
States / cities: Stanford, California • Bridgeport, Connecticut • Gainsville, Florida + 11 more

Conditions: Bleeding, Platelet Dysfunction Due to Drugs, Platelet Dysfunction
Interventions: Autologous Platelet Transfusion (room-temperature-stored), Autologous Platelet Transfusion (cold-stored 5 days), Autologous Platelet Transfusion (cold-stored 10 days), Autologous Platelet Transfusion (cold-stored 15 days), Aspirin, Clopidogrel; Drug
Lead sponsor: Bloodworks; Other
Eligibility: 18 Years to 59 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Blunt Cerebrovascular Injury
Interventions: Aspirin 325Mg Tab, Aspirin 81Mg Tab; Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Osteoarthritis
Interventions: Aspirin, Portable Compression Device; Drug · Device
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Stroke, Transient Ischemic Attack (TIA)
Interventions: CYP2C19 Genotype Guided DAPT (dual antiplatelet therapy); Genetic
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 89 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Platelet Activation Testing Before/After Anti-platelet Therapy, Healthy
Interventions: Aspirin, Clopidogrel; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Stroke
Interventions: Active Aspirin, Active Warfarin, Aspirin placebo, Warfarin placebo; Drug
Lead sponsor: Columbia University; Other
Eligibility: 30 Years to 85 Years
Enrollment: 2,206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2001
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Body Weight, Aspirin Dose and Pro-resolving Mediators

The Clinical Utility of Thrombelastography in Guiding Prophylaxis of Venous Thromboembolism Following Trauma

Salicylic Augmentation in Depression

PFA 100 Evaluation and Reference Interval HOACNY

GM03 - Platelet RNA Signatures of Aspirin

Using Aspirin to Improve Immunological Features of Ovarian Tumors

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

Aspirin and Antiretroviral Therapy in HIV Infected Patients

Alternative Options to Minimize Niacin-Induced Flushing

Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma

Effect of Aspirin on Gut Microbiome

Endoscopic Evaluation of Upper Gastrointestinal (GI) Mucosal Damage Induced by PL-2200 Versus Aspirin in Healthy Volunteers

Effects of ASA on Prostate Tissue

Asprin Dosing Estimator in Healthy Adults

Alleviation of Common Cold Symptoms

Effect of Postoperative Ketorolac on Bone Healing After Joint Fusion

Aspirin Resistance and Percutaneous Coronary Intervention (PCI)

LIPS-A: Lung Injury Prevention Study With Aspirin

Reversal of Dual Antiplatelet Therapy With Cold Stored Platelets

Stroke Rate in Patients With Blunt Cerebrovascular Injury (BCVI) Treated With Oral Acetylsalicylic Acid (ASA) 81 mg Versus ASA 325 mg (BASA).

Evaluating the Need for Pneumatic Compression Devices

Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing

The Accuracy Of A Novel Platelet Activity Assay In Humans On Antiplatelet Agents: Pharmacodynamics And Comparison With Light Transmission Aggregometry

Warfarin Versus Aspirin Recurrent Stroke Study